Your Trusted Brand for Over 35 Years

Lung Cancer References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Jemal A, Siegel R et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar;56(2):106–30.
  2. Gloeckler Ries LA, Reichman ME et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6):541–52.
  3. Sugimura H, Yang P. Long-term survivorship in lung cancer: A review. Chest. 2006 Apr;129(4):1088–97.
  4. Toh CK, Gao F et al. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006 May 20;24(15):2245–51.
  5. Vukovic B, Faj D et al. Indoor radon and lung cancer: A case-control study. Isotopes Environ Health Stud. 2005 Jun;41(2):169–76.
  6. van Zandwijk N. Chemoprevention in lung carcinogenesis—an overview. Eur J Cancer. 2005 Sep;41(13):1990–2002.
  7. Saba NF, Khuri FR. Chemoprevention strategies for patients with lung cancer in the context of screening. Clin Lung Cancer. 2005 Sep;7(2):92–9.
  8. European Lung Cancer Working Party. [Management of resectable non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux. 2006 Jan;27(1):29–38.
  9. Jatoi A, Williams BA et al. Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: Results from the Mayo Clinic lung cancer cohort. Nutr Cancer. 2005b;51(1):7–12.
  10. Toyooka S, Pass HI et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res. 2001 Aug 1;61(15):5727–30.
  11. Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005 Sep;33(3):216–23.
  12. Philip M, Rowley DA et al. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec;14(6):433–9.
  13. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst. 1963 Feb;30:289–312.
  14. Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks. 2005;53(2):200–9.
  15. Minna JD. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest. 2003 Jan;111(1):31–3.
  16. L F, M E et al. [Efficacy of different smoking cessation treatments.] Rev Port Pneumol. 2005 Nov;11(6 Suppl 1):42–3.
  17. Lee HJ, Lee JH. Effects of medicinal herb tea on the smoking cessation and reducing smoking withdrawal symptoms. Am J Chin Med. 2005a;33(1):127–38.
  18. Vastag B. Attention turns to lung cancer in nonsmokers. J Natl Cancer Inst. 2006 May 17;98(10):664–5.
  19. Gorlova OY, Zhang Y et al. Never smokers and lung cancer risk: A case-control study of epidemiological factors. Int J Cancer. 2006 Apr 1;118(7):1798–804.
  20. Matakidou A, Eisen T et al. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer. 2005 Oct 3;93(7):825–33.
  21. Kleinerman RA, Tarone RE et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000 Dec 20;92(24):2037–9.
  22. Zalcman G, Tredaniel J et al. [The p53 gene and protein in bronchial carcinogenesis: From biological to clinical aspects]. Rev Mal Respir. 1994;11(5):455–72.
  23. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol. 2003 Jun;24(2):141–56.
  24. Horowitz JM, Park SH et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2775–9.
  25. Chen YC, Chen JH et al. Lung adenocarcinoma and human papillomavirus infection. Cancer. 2004 Sep 15;101(6):1428–36.
  26. Minna JD, Fong K et al. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 2002 May;8 Suppl 1:S41–S46.
  27. Hertz-Picciotto I, Smith AH. Observations on the dose-response curve for arsenic exposure and lung cancer. Scand J Work Environ Health. 1993 Aug;19(4):217–26.
  28. van Zandwijk N, Dalesio O et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst. 2000 Jun 21;92(12):977–86.
  29. Godtfredsen NS, Prescott E et al. Effect of smoking reduction on lung cancer risk. JAMA. 2005 Sep 28;294(12):1505–10.
  30. Mannisto S, Smith-Warner SA et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):40–8.
  31. Yuan JM, Ross RK et al. Prediagnostic levels of serum beta-cryptoxanthin and retinol predict smoking-related lung cancer risk in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):767–73.
  32. Knekt P, Jarvinen R, et al. Role of various carotenoids in lung cancer prevention. J Natl Cancer Inst. 1999 Jan 20;91(2):182–4.
  33. Le ML, Hankin JH et al. Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 1993 May;2(3):183–7.
  34. Moysich KB, Menezes RJ et al. Regular aspirin use and lung cancer risk. BMC Cancer. 2002 Nov 26;2:31.
  35. Heimburger DC, Alexander CB et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA. 1988 Mar 11;259(10):1525–30.
  36. Kubik A, Zatloukal P et al. Lung cancer risk among nonsmoking women in relation to diet and physical activity. Neoplasma. 2004;51(2):136–43.
  37. Wang J, Huang C et al. [Research progress on dietary fat and the development of lung cancer]. Wei Sheng Yan Jiu. 2004 May;33(3):383–5.
  38. Takezaki T, Inoue M et al. Diet and lung cancer risk from a 14-year population-based prospective study in Japan: With special reference to fish consumption. Nutr Cancer. 2003;45(2):160–7.
  39. Gao CM, Tajima K et al. Protective effects of raw vegetables and fruit against lung cancer among smokers and ex-smokers: A case-control study in the Tokai area of Japan. Jpn J Cancer Res. 1993 Jun;84(6):594–600.
  40. Lam WK, White NW et al. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis. 2004 Sep;8(9):1045–57.
  41. Shao J, Dai J et al. A pilot study on anticancer activities of Chinese leek. J Altern Complement Med. 2001 Oct;7(5):517–22.
  42. Fabricius P, Lange P. Diet and lung cancer. Monaldi Arch Chest Dis. 2003 Jul;59(3):207–11.
  43. Fontham ET. Protective dietary factors and lung cancer. Int J Epidemiol. 1990;19 Suppl 1:S32–S42.
  44. Biesalski HK, Bueno de MB et al. European consensus statement on lung cancer: Risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin. 1998 May;48(3):167–76.
  45. Ferrigno D, Buccheri G et al. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001 Apr;17(4):667–73.
  46. Kostecka IA, Haponowicz B et al. [Concentration of prothrombin fragments 1+2 (F1+2) and thrombin-antithrombin III complexes (TAT) in patients with primary non-small cell lung cancer, before and after resection]. Przegl Lek. 2000;57(9):451–4.
  47. Tomita M, Matsuzaki Y et al. Prognostic determinants for lung cancer patients with preoperative high serum carcinoembryonic antigen levels. Thorac Cardiovasc Surg. 2005 Oct;53(5):300–4.
  48.      Komagata H, Yoneda S. [Lung cancer]. Gan To Kagaku Ryoho. 2004 Oct;31(10): 1609–13.
  49. Ferrigno D, Buccheri G et al. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003 Sep;41(3):311–20.
  50. Satoh H, Ishikawa H et al. Elevated serum sialyl Lewis X-i antigen levels in non-small cell lung cancer with lung metastasis. Respiration. 1998;65(4):295–8.
  51. Chantapet P, Riantawan P et al. Utility of serum cytokeratin 19 fragment (CYFRA 21–1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer. J Med Assoc Thai. 2000 Apr;83(4):383–91.
  52. Molina R, Filella X et al. Tumor markers (CEA, CA 125, CYFRA 21–1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003 Aug;24(4):209–18.
  53. Molina R, Filella X et al. ProGRP: A new biomarker for small cell lung cancer. Clin Biochem. 2004 Jul;37(7):505–11.
  54. Scagliotti GV, Novello S. Adjuvant therapy in completely resected non-small-cell lung cancer. Curr Oncol Rep. 2003 Jul;5(4):318–25.
  55. Saha P, Banerjee S et al. Black tea extract can modulate protein expression of H-ras, c-Myc, p53, and Bcl-2 genes during pulmonary hyperplasia, dysplasia, and carcinoma in situ. J Environ Pathol Toxicol Oncol. 2005;24(3):211–24.
  56. Cerchietti LC, Navigante AH et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study. J Pain Symptom Manage. 2004 Jan;27(1):85–95.
  57. Yang P, Chan D et al. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res. 2004 Jun;45(6):1030–9.
  58. Lee E, Choi MK et al. Alpha-tocopheryl succinate, in contrast to alpha-tocopherol and alpha-tocopheryl acetate, inhibits prostaglandin E2 production in human lung epithelial cells. Carcinogenesis. 2006 May 19.
  59. Banerjee S, Panda CK et al. Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer. Carcinogenesis. 2006 Feb 25. [Epub ahead of print]
  60. Harris RE, Beebe-Donk J et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005 Apr;13(4):559–83.
  61. Mascaux C, Iannino N et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer. 2005 Jan 17;92(1):131–9.
  62. Slebos RJ, Kibbelaar RE et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990 Aug 30;323(9):561–5.
  63. Zajac-Kaye M. Myc oncogene: A key component in cell cycle regulation and its implication for lung cancer. Lung Cancer. 2001 Dec;34 Suppl 2:S43–S46.
  64. Yakut T, Egeli U et al. Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: By the FISH technique. Lung. 2003;181(5):245–58.
  65. Su C, Ye Y et al. [Analysis on point mutation of the CDKN2/p16 gene in lung cancer]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Feb;19(1):37–40.
  66. Minamoto T, Mai M et al. K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers—a review. Cancer Detect Prev. 2000;24(1):1–12.
  67. Xu M, Floyd HS et al. Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: Potential mechanisms for its chemotherapeutic effects. Toxicol Appl Pharmacol. 2004 Mar 1;195(2):232–46.
  68. Lantry LE, Zhang Z et al. Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung. J Cell Biochem Suppl. 1997;27:20–5.
  69. Lin JK. Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways. Arch Pharm Res. 2002 Oct;25(5):561–71.
  70. Bagchi D, Bagchi M et al. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci. 2002 May;957:260–70.
  71. Chandra V, Allen MS et al. The role of pulmonary resection in small cell lung cancer. Mayo Clin Proc. 2006 May;81(5):619–24.
  72. Raez L, Samuels M et al. Combined modality therapy for limited-disease small cell lung cancer. Curr Treat Options Oncol. 2005 Jan;6(1):69–74.
  73. Rostad H, Naalsund A et al. Small cell lung cancer in Norway: Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg. 2004 Oct;26(4):782–6.
  74. Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin. 2004 May;14(2):271–81.
  75. Nesbitt JC, Putnam JB Jr et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995 Aug;60(2):466–72.
  76. Zhou W, Suk R et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303–9.
  77. Erhola M, Nieminen MM et al. Effects of surgical removal of lung cancer on total plasma antioxidant capacity in lung cancer patients. J Exp Clin Cancer Res. 1998 Jun;17(2):219–25.
  78. Silvano G. New radiation techniques for treatment of locally advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2006 Mar;17 Suppl 2:ii34–ii35.
  79. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998 Jul 25;352(9124):257–63.
  80. Machtay M, Lee JH et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001 Oct 1;19(19):3912–7.
  81. Chang JY, Zhang X et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1087-96.
  82. Engelsman M, Rietzel E et al. Four-dimensional proton treatment planning for lung tumors. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1589–95.
  83. Fanta J, Lang O et al. [Lung resection for a non-small cell carcinoma (stage IV) with a permanent intracavitary brachytherapy 125I]. Rozhl Chir. 2006 Feb;85(2):67–70.
  84. Keall P, Vedam S et al. The clinical implementation of respiratory-gated intensity-modulated radiotherapy. Med Dosim. 2006;31(2):152–62.
  85. Nagata Y, Takayama K et al. [Stereotactic body radiotherapy (SBRT)]. Gan To Kagaku Ryoho. 2006 Apr;33(4):455–61.
  86. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):5–24.
  87. Wagner H, Jr. Prophylactic cranial irradiation for patients with small cell lung cancer: An enduring controversy. Chest Surg Clin N Am. 1997 Feb;7(1):151–66.
  88. Misirlioglu CH, Erkal H et al. Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: A randomized prospective clinical trial. Med Oncol. 2006;23(2):185–90.
  89. Wang SQ. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases]. Zhonghua Zhong Liu Za Zhi. 1991 Jan;13(1):71–3.
  90. Smolanka II. [Systemic enzyme therapy with the preparation Wobe-Mugos E in the combined treatment of lung cancer patients]. Lik Sprava. 2000 Jul;(5):121–3.
  91. Huang CL, Yokomise H et al. Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2006 Apr;2(2):289–99.
  92. Eckardt JR, von PJ et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2044–51.
  93. Winton T, Livingston R et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589–97.
  94. Alam N, Darling G et al. Postoperative chemotherapy in nonsmall cell lung cancer: A systematic review. Ann Thorac Surg. 2006 May;81(5):1926–36.
  95. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol. 1998 Jan;30(1):1–4.
  96. Altinbas M, Coskun HS et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004 Aug;2(8):1266–71.
  97. Udut EV, Zhdanov VV et al. [Mechanisms of the erythropoiesis-stimulating effect of skullcap (Scutellaria baicalensis) extract]. Eksp Klin Farmakol. 2005 Jul;68(4):43–5.
  98. Gol’dberg VE, Ryzhakov VM et al. [Dry extract of Scutellaria baicalensis as a hemostimulant in antineoplastic chemotherapy in patents with lung cancer]. Eksp Klin Farmakol. 1997 Nov;60(6):28–30.
  99. Pathak AK, Bhutani M et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005 Feb;24(1):16–21.
  100. Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. Cancer Biother Radiopharm. 2006 Feb;21(1):68–73.
  101. Von Hoff DD. He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst. 1990 Jan 17;82(2):96–101.
  102. Thunnissen FB, Schuurbiers OC et al. A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology. 2006 Jun;48(7):779–86.
  103. Kwon WS, Rha SY et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 2006 Jun;16(6):429–38.
  104. Ploylearmsaeng SA, Fuhr U et al. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45(6):567–92.
  105. Takizawa M, Kawakami K et al. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep. 2006 Jun;15(6):1533–9.
  106. Tokumo M, Toyooka S et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer. 2006 Jul;53(1):117–21.
  107. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005 Jan;5(1):73–88.
  108. Rosell R, Cuello M et al. Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going. Curr Opin Oncol. 2006 Mar;18(2):135–43.
  109. Santarpia M, Altavilla G et al. From the bench to the bed: Individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol. 2006 Feb;8(2):71–6.
  110. Zhou XD, Cai WQ et al. [Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]. Ai Zheng. 2002 Mar;21(3):259–62.
  111. Bhatavdekar JM, Patel DD et al. Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma. 1994;41(2):101–3.
  112. Inoue M, Minami M et al. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: Pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement. J Thorac Cardiovasc Surg. 2006 May;131(5):988–93.
  113. Liu Y, Inoue M et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: A large-scale population-based cohort study. Int J Cancer. 2005a Nov 20;117(4):662–6.
  114. Canver CC, Memoli VA et al. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg. 1994 Jul;108(1):153–7.
  115. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987 Jan;45(1 Suppl):277–82.
  116. Sanchez-Barcelo EJ, Cos S et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005 May;38(4):217–22.
  117. Rato AG, Pedrero JG et al. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999 May;13(8):857–68.
  118. Otsuka M, Kato N et al. Vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sci. 2005 Apr 8;76(21):2473–82.
  119. Deslypere JP. Obesity and cancer. Metabolism. 1995 Sep;44(9 Suppl 3):24–7.
  120. Alavanja MC, Swanson C et al. Re: Lung cancer: Another consequence of a high-fat diet? J Natl Cancer Inst. 1994 Feb 16;86(4):314.
  121. Kolonel LN. Lung cancer: Another consequence of a high-fat diet? J Natl Cancer Inst. 1993 Dec 1;85(23):1886–7.
  122. Moody TW. Peptide hormones and lung cancer. Panminerva Med. 2006 Mar;48(1):19–26.
  123. Moody TW, Chiles J et al. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 2001 Jan;22(1):109–15.
  124. Lissoni P, Rovelli F et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;22(1):45–7.
  125. Lynch E. Melatonin and cancer treatment. European Biology and Bioelectromagnetics. 2005 Jun 18;1(2):183–200.
  126. Mazzoccoli G, Giuliani A et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: Temporal relationship with growth hormone (GH) levels. Anticancer Res. 1999 Mar;19(2B):1397–9.
  127. Levin RD, Daehler MA et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005 Nov 28;93(11):1202–8.
  128. Lissoni P, Giani L et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun. 1998;16(1):27–33.
  129. Lissoni P, Barni S et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999 Nov;35(12):1688–92.
  130. Lissoni P, Chilelli M et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res. 2003a Aug;35(1):12–5.
  131. Lissoni P, Malugani F et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro Endocrinol Lett. 2003b Feb;24(1-2):83–5.
  132. Hondeghem LM. Antiarrhythmic agents: Modulated receptor applications. Circulation. 1987 Mar;75(3):514–20.
  133. Hercbergs A, Leith JT. Spontaneous remission of metastatic lung cancer following myxedema coma—an apoptosis-related phenomenon? J Natl Cancer Inst. 1993 Aug 18;85(16):1342–3.
  134. Hercbergs A. Spontaneous remission of cancer—a thyroid hormone dependent phenomenon? Anticancer Res. 1999 Nov;19(6A):4839–44.
  135. Garfield D. Hypothyroidism promotes survival. Lancet Oncol. 2002 Jun;3(6):328.
  136. Jatoi A, Williams B et al. Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005a Jul;49(1):77–84.
  137. Patel D, Shukla, S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol. 2007;30(1):233-45.
  138. Liu LZ, Fang J, Zhou Q, et al. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol. 2005b Sep;68(3):635-43.
  139. Ren HY, Tang XW. [Anti-proliferation and chemo-sensitization effects of apigenin on human lung cancer cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011 Sep;40(5):508-14.
  140. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol. 1988 Aug;26(4):183-7.
  141. Cho WC, Leung KN. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol. 2007a Aug 15;113(1):132-41.
  142. Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007b Jul 8;252(1):43-54.
  143. Zou YH, Liu XM. Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Oct;23(10):733-5.
  144. McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006 Jan 20;24(3):419-30.
  145. Wiers KM, Lathers DM et al. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. J Immunother. 2000 Jan;23(1):115–24.
  146. Haskell CM, Mendoza E et al. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs. 1998;16(1):81–5.
  147. Agteresch HJ, Burgers SA et al. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs. 2003 Sep;14(8):639–44.
  148. Leij-Halfwerk S, Agteresch HJ et al. Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: An in vivo 31P magnetic resonance spectroscopy study. Hepatology. 2002 Feb;35(2):421–4.
  149. Agteresch HJ, Rietveld T et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: A randomized clinical trial. J Clin Oncol. 2002 Jan 15;20(2):371–8.
  150. Agteresch HJ, Dagnelie PC et al. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol. 2000 Apr;56(1):49–55.
  151. Maymon R, Bar-Shira MB et al. Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines. Biochim Biophys Acta. 1994 Nov 11;1201(2):173–8.
  152. Estrela JM, Obrador E et al. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med. 1995 Jan;1(1):84–8.
  153. Senagore AJ, Milsom JW et al. Adenosine triphosphate-magnesium chloride in radiation injury. Surgery. 1992 Nov;112(5):933–9.
  154. Laurie SA, Miller VA et al. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol. 2005 Jan;55(1):33–8.
  155. Pisters KM, Newman RA et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001 Mar 15;19(6):1830–8.
  156. Lu YP, Lou YR et al. Stimulatory effect of oral administration of green tea or caffeine on ultraviolet light-induced increases in epidermal wild-type p53, p21(WAF1/CIP1), and apoptotic sunburn cells in SKH-1 mice. Cancer Res. 2000 Sep 1;60(17):4785–91.
  157. Xu Y, Ho CT et al. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 1992 Jul 15;52(14):3875–9.
  158. Woodson K, Tangrea JA et al. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst. 1999 Oct 20;91(20):1738–43.
  159. Syed DN, Chamcheu JC, Mukhtar VM. Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activies. Anticancer Agents Med Chem. 2012 Oct 12.
  160. Johanningsmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. Annu Rev Food Sci Technol. 2011;9:188-201.
  161. Khan N, Afaq F, Kweon MH, et at. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res. 2007a Apr 1;67(7):3475-82.
  162. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis. 2007b Jan;28(1):163-73.
  163. Koda K, Miyazaki M et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.Int J Oncol . 2003;23(1):165-72.
  164. Noguchi K, Tanimura H et al. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.Anticancer Res . 1995;15(2):255-8.
  165. Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.Anticancer Res . 1997;17(4A):2815-8.
  166. Zhang H, Morisaki T et al. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.Clin Exp Metastasis . 2000;18(4):343-52.
  167. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep. 2006 Apr;15(4):861-8.
  168. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May;22(3):1737-54.
  169. Garcia-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate difference nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother. 2001 Jun;50(4):191-8.
  170. Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 1999;29(4):135-40.
  171. Hayakawa K, Mitsuhashi N, Saito Y et al. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997;21(1):71-7.
  172. Hayakawa K, Mitsuhashi N, Saito Y et al. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res. 1993 Sep-Oct;13(5C):1815-20.
  173. Aherne SA, O'Brien NM. Protection by the flavonoids myricetin, quercetin, and rutin against hydrogen peroxide-induced DNA damage in Caco-2 and Hep G2 cells. Nutr Cancer. 1999;34(2):160-6.
  174. Yang JH, Hsia TC, Kuo HM, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos. 2006 Feb;34(2):296-304.
  175. Morrow DM, Fitzsimmons PE, Chopra M, et al. Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res. 2001 Sep 1;480-481:269-76.
  176. Bach A, Bender-Sigel J, Schrenk D, Flugel D, Kietzmann T. The antioxidant quercetin inhibits cellular proliferation via HIF-1-dependent induction of p21WAF. Antioxid Redox Signal. 2010 Aug 15;13(4):437-48.
  177. Zheng SY, Li Y, Jiang D, et al. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol Med Report. 2012 Mar;5(3):822-6.
  178. Kamaraj S, Vinodhkumar R, Anandakumar P, et al. The effects of quercetin on antioxidant status and tumor markers in the lung and serum of mice treated with benzo(a)pyrene. Biol Pharm Bull. 2007 Dec;30(12):2268-73.
  179. Rayman MP. Selenium in cancer prevention: A review of the evidence and mechanism of action. Proc Nutr Soc. 2005 Nov;64(4):527–42.
  180. Zhuo H, Smith AH et al. Selenium and lung cancer: A quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):771–8.
  181. Reid ME, Duffield-Lillico AJ et al. Selenium supplementation and lung cancer incidence: An update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1285–91.
  182. Miyamoto H, Araya Y et al. Serum selenium and vitamin E concentrations in families of lung cancer patients. Cancer. 1987 Sep 1;60(5):1159–62.
  183. Neve J. Selenium as a ‘nutraceutical’: How to conciliate physiological and supra-nutritional effects for an essential trace element. Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):659–63.
  184. Maasilta P, Holsti LR et al. N-acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: A feasibility study. Radiother Oncol. 1992 Nov;25(3):192–5.
  185. Jepsen S, Nielsen PH et al. Peroral N-acetylcysteine as prophylaxis against bronchopulmonary complications of pulmonary surgery. Scand J Thorac Cardiovasc Surg. 1989;23(2):185–8.
  186. Mantovani G, Madeddu C et al. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: Phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol. 2003 Jul;3(4):205–19.
  187. Evans WK, Nixon DW et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987 Jan;5(1):113–24.
  188. Takeda Y, Tsuduki E et al. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005 Dec 12;93(12):1341–9.
  189. Lee J, Im YH et al. Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. Biochem Biophys Res Commun. 2005b Aug 26;334(2):313–8.
  190. Panwar M, Samarth R, et al. Inhibition of benzo(a)pyrene induced lung adenoma by panax ginseng extract, EFLA400, in Swiss albino mice. Biol Pharm Bull. 2005 Nov;28(11):2063–7.
  191. Wu XJ, Kassie F et al. The role of reactive oxygen species (ROS) production on diallyl disulfide (DADS) induced apoptosis and cell cycle arrest in human A549 lung carcinoma cells. Mutat Res. 2005 Nov 11;579(1-2):115–24.
  192. Arab L, Steck-Scott S et al. Lycopene and the lung. Exp Biol Med (Maywood). 2002 Nov;227(10):894–9.
  193. de Bravo MG, Tournier H et al. [Effect of dietary supplementation with gamma-linolenic acid on the growth of a human lung carcinoma implanted in nude mice]. Medicina (B Aires). 1995;55(6):670–4.
  194. Chen PN, Hsieh YS et al. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005 Oct 20;156(2-3):141–50.
  195. Lei W, Mayotte JE et al. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. Biochem Biophys Res Commun. 1998 Apr 28;245(3):939–45.
  196. Lei W, Mayotte JE et al. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res. 1999 Jan;19(1A):221–8.
  197. Holick CN, Michaud DS et al. Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study. Am J Epidemiol. 2002 Sep 15;156(6):536–47.
  198. Johnson EJ. The role of carotenoids in human health. Nutr Clin Care. 2002 Mar;5(2):56–65.
  199. Schabath MB, Hernandez LM et al. Dietary phytoestrogens and lung cancer risk. JAMA. 2005 Sep 28;294(12):1493–504.
  200. Menon LG, Kuttan R et al. Effect of isoflavones genistein and daidzein in the inhibition of lung metastasis in mice induced by B16F-10 melanoma cells. Nutr Cancer. 1998;30(1):74–7.
  201. Albanes D, Heinonen OP et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996 Nov 6;88(21):1560–70.
  202. Galan P, Briancon S et al. Antioxidant status and risk of cancer in the SU.VI.MAX study: Is the effect of supplementation dependent on baseline levels? Br J Nutr. 2005 Jul;94(1):125–32.
  203. Ratnasinghe D, Tangrea JA et al. Influence of antioxidants and the CYP1A1 isoleucine to valine polymorphism on the smoking-lung cancer association. Anticancer Res. 2001 Mar;21(2B):1295–9.
  204. Zhong L, Goldberg MS et al. A population-based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology. 2001 Nov;12(6):695–700.
  205. Clark J, You M. Chemoprevention of lung cancer by tea. Mol Nutr Food Res. 2006 Feb;50(2):144–51.